Neurobiology of Aging
Volume 31, Issue 4 , Pages 542-548 , April 2010

Molecular polymorphism of Aβ in Alzheimer's disease

  • Harry LeVine III

      Affiliations

    • Department of Molecular and Cellular Biochemistry, Chandler School of Medicine and the Center on Aging, University of Kentucky, Lexington, KY, USA
    • Corresponding Author InformationCorresponding author at: 209 Sanders-Brown Building, 800 South Limestone Street, Lexington, KY 40536-0230, USA. Tel.: +859 257 1412x224; fax: +859 323 2866.
    • ,
  • Lary C. Walker

      Affiliations

    • Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, GA, USA

Received 24 March 2008 ,Accepted 28 May 2008.

References 

  1. Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell. Biol. 2007;8(7):552–561
  2. Aslund A, Herland A, Hammarstrom P, Nilsson KP, Jonsson BH, Inganas O, et al. Studies of luminescent conjugated polythiophene derivatives: enhanced spectral discrimination of protein conformational states. Bioconjug. Chem. 2007;18(4):1860–1868
  3. Attems J, Lintner F, Jellinger KA. Amyloid beta peptide 1–42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. (Berl.). 2004;107(4):283–291
  4. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837–1844
  5. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 1995;52(1):81–88
  6. Chandra R, Kung MP, Kung HF. Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg. Med. Chem. Lett. 2006;16(5):1350–1352
  7. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930–936
  8. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 1988;38(11):1682–1687
  9. Eriksen JL, Janus CG. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Gen. 2007;37(1):79–100
  10. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 2007;27(39):10365–10371
  11. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G.,Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., 2007. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2007.03.029, in press.
  12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  13. Ikeda S, Allsop D, Glenner GG. Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab. Invest. 1989;60(1):113–122
  14. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(6):1630–1645
  15. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 2007;
  16. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002;41(3):922–928
  17. Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006;413:326–344
  18. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007;2(1):18
  19. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68(19):1603–1606
  20. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55(3):306–319
  21. Klunk WE, Lopresti BJ, Debnath ML, Holt DP, Wang Y, Huang G-F, et al. Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid PET tracer, PIB, in the same manner as human brain amyloid. Neurobiol. Aging. 2004;25(S2):232
  22. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 2003;23(6):2086–2092
  23. Kung, M.P., Hou., C., Zhuang, Z.P., Cross, A.J., Maier, D.L., Kung, H.F., 2004. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur. J. Nucl. Med. Mol. Imag. (10.1007/S00259-004-1487-z).
  24. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. 2002;956(2):202–210
  25. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001;276(16):12991–12998
  26. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 2007;100(1):23–35
  27. LeVine H. Y10W beta(1–40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide. Arch. Biochem. Biophys. 2003;417(1):112–122
  28. LeVine H. Multiple ligand binding sites on A beta(l–40) fibrils. Amyloid. 2005;12(1):5–14
  29. LeVine H, Walker LC. Chapter 11. Models of Alzheimer's disease. In:  Conn MP editors. Handbook of Models for Human Aging. New York, NY: Academic Press/Elsevier; 2006;p. 121–134
  30. Lim KH, Nguyen TN, Damo SM, Mazur T, Ball HL, Prusiner SB, et al. Solid-state NMR structural studies of the fibril form of a mutant mouse prion peptide PrP89-143(P101L). Solid State Nucl. Magn. Reson. 2006;29(1–3):183–190
  31. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain. 2007;130(10):2607–2610
  32. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J. Biol. Chem. 2005;280(9):7677–7684
  33. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007;27(41):10957–10968
  34. Matsunaga Y, Saito N, Fujii A, Yokotani J, Takakura T, Nishimura T, et al. A pH-dependent conformational transition of Abeta peptide and physicochemical properties of the conformers in the glial cell. Biochem. J. 2002;361(Pt 3):547–556
  35. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781–1784
  36. Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry. 2003;42(40):11682–11692
  37. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, Clair DKS, et al. Aβ solubility and deposition during AD progression and in APPXPS1 Knock-in mice. Neurobiol. Dis. 2007;
  38. Nilsson KP, Aslund A, Berg I, Nystrom S, Konradsson P, Herland A, et al. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem. Biol. 2007;2(8):553–560
  39. O’Nuallain B, Wetzel R. Conformational antibodies recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U.S.A. 2002;99(3):1485–1490
  40. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307(5707):262–265
  41. Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry. 2006;45(2):498–512
  42. Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205–1212
  43. Rosen RF, LeVine H, Walker LC. PIB binding in Alzheimer's disease and nonhuman primate brain. In: Proceedings of the 11th International Conference on Alzheimer's Disease and Related Disorders. Chicago, IL. 2008;
  44. Somerville RA. Host and transmissible spongiform encephalopathy agent strain control glycosylation of PrP. J. Gen. Virol. 1999;80(Pt 7):1865–1872
  45. Tagliavini F, Giaccone G, Frangione B, Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci. Lett. 1988;93(2–3):191–196
  46. Toyama BH, Kelly MJ, Gross JD, Weissman JS. The structural basis of yeast prion strain variants. Nature. 2007;449(7159):233–237
  47. Walker L, LeVine H, Jucker M. Koch's postulates and infectious proteins. Acta Neuropathol. 2006;112(1):1–4
  48. Weissmann C. The state of the prion. Nat. Rev. Microbiol. 2004;2(11):861–871
  49. Wetzel R, Shivaprasad S, Williams AD. Plasticity of amyloid fibrils. Biochemistry. 2007;46(1):1–10
  50. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci. 1982;56(2–3):343–356
  51. Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie J. Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. Acta Neuropathol. (Berl.). 1989;78(4):337–347
  52. Yagi H, Ban T, Morigaki K, Naiki H, Goto Y. Visualization and classification of amyloid beta supramolecular assemblies. Biochemistry. 2007;46(51):15009–15017
  53. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol. 1988;76(6):541–549
  54. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of PET imaging agent binding sites on beta -amyloid peptide fibrils. J. Biol. Chem. 2005;280(25):23599–23604
  55. Yoshiike Y, Kayed R, Milton SC, Takashima A, Glabe CG. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromol. Med. 2007;9(3):270–275
  56. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006;16(1):30–39

PII: S0197-4580(08)00182-6

doi: 10.1016/j.neurobiolaging.2008.05.026

Neurobiology of Aging
Volume 31, Issue 4 , Pages 542-548 , April 2010

Article Tools

* Image Usage & Resolution